No Data
No Data
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics Strengthens Legal Safeguards for Leadership
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns maintains $Fate Therapeutics(FATE.US)$ with a hold rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.6%
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)